October 5, 2011

Failing grade for diabetic neuropathy drug trials


A drug being tested for diabetic nerve pain has failed to meet its goals in the mid-stage clinical trials.

Sangamo BioSciences Inc. was developing a drug to treat diabetic nerve pain. The results from the mid-stage trials were not shown to be  significantly more effective than a placebo.

The drug being developed is known in the pipleline as SB-509. In theory the drug would work by encouraging the regrowth and restoration of damaged nerves

Diabetic nerve pain (diabetic neuropathy) is a force to be reckoned with. Approximately 60-70% of those with diabetes have some form of neuropathy and the longer a person has diabetes the greater their risk of developing this condition.

Everything from anti-depressants (Lyrica and Cymbalta) to seizure medicines (Topamax) are prescribed to treat the condition. However these drugs do not retard or reverse the progression of the disease. This is where Sangamo BioSciences hopes to become the first of its kind.

In the wise words of Winston Churchill, “Success is not final, failure is not fatal: it is the courage to continue that counts.”¬† For all living with diabetic nerve pain – this may be impetus for the courage to continue in the pursuit of the drug that can arrest diabetic nerve pain and regrow and restore the nerves.

For your friendly guidance on a diabetes research  check out https://www.thediabetesresource.com.